Subjects

Abstract

Purpose

To enhance classification of variants of uncertain significance (VUS) in the DNA mismatch repair (MMR) genes in the cancer predisposition Lynch syndrome, we developed the cell-free in vitro MMR activity (CIMRA) assay. Here, we calibrate and validate the assay, enabling its integration with in silico and clinical data.

Methods

Two sets of previously classified MLH1 and MSH2 variants were selected from a curated MMR gene database, and their biochemical activity determined by the CIMRA assay. The assay was calibrated by regression analysis followed by symmetric cross-validation and Bayesian integration with in silico predictions of pathogenicity. CIMRA assay reproducibility was assessed in four laboratories.

Results

Concordance between the training runs met our prespecified validation criterion. The CIMRA assay alone correctly classified 65% of variants, with only 3% discordant classification. Bayesian integration with in silico predictions of pathogenicity increased the proportion of correctly classified variants to 87%, without changing the discordance rate. Interlaboratory results were highly reproducible.

Conclusion

The CIMRA assay accurately predicts pathogenic and benign MMR gene variants. Quantitative combination of assay results with in silico analysis correctly classified the majority of variants. Using this calibration, CIMRA assay results can be integrated into the diagnostic algorithm for MMR gene variants.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015;15:181–194.

  2. 2.

    Tavtigian SV, Chenevix-Trench G. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Biomark Med. 2014;8:589–603.

  3. 3.

    LaDuca H, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014;16:830–837.

  4. 4.

    Slavin TP, et al. Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management. Front Oncol. 2015;5:208.

  5. 5.

    Susswein LR, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med. 2016;18:823–832.

  6. 6.

    Hermel, DJ, McKinnon, WC, Wood, ME & Greenblatt, MS Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. Fam Cancer 2016;163:383–390.

  7. 7.

    Goldgar DE, et al. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat. 2008;29:1265–1272.

  8. 8.

    Plon SE, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–1291.

  9. 9.

    Sijmons RH, Greenblatt MS, Genuardi M. Gene variants of unknown clinical significance in Lynch syndrome. An introduction for clinicians. Fam Cancer. 2013;12:181–187.

  10. 10.

    Thompson BA, et al. A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. Hum Mutat. 2013;34:200–209.

  11. 11.

    Thompson BA, et al. Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat. 2013;34:255–265.

  12. 12.

    Thompson BA, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2014;46:107–115.

  13. 13.

    Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–423.

  14. 14.

    Rasmussen LJ. et al. Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future. Hum Mutat. 2012;33:1617–1625.

  15. 15.

    Peña-Diaz J, Rasmussen LJ. Approaches to diagnose DNA mismatch repair gene defects in cancer. DNA Repair (Amst). 2016;38:147–154.

  16. 16.

    Goldgar DE, et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004;75:535–544.

  17. 17.

    Easton DF, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007;81:873–883.

  18. 18.

    Tavtigian SV. et al. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med. 2018;20:1054–1060.

  19. 19.

    Vallee MP, et al. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat. 2012;33:22–28.

  20. 20.

    Drost M, et al. A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1. Hum Mutat. 2010;31:247–253.

  21. 21.

    Drost M, et al. A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants. Hum Mutat. 2012;33:488–494.

  22. 22.

    Drost M, Koppejan H, de Wind N. Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene. Hum Mutat. 2013;34:1477–1480.

  23. 23.

    Tavtigian, SV & Greenblatt, MS. R01CA164944: Classifying DNA Mismatch Repair Gene Variants of Unknown Significance. (2013).

  24. 24.

    Holmes J, Clark S, Modrich P. Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci U S A. 1990;87:5837–5841.

  25. 25.

    Raevaara TE, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology. 2005;129:537–549.

  26. 26.

    Ollila S, et al. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology. 2006;131:1408–1417.

  27. 27.

    Working H, Hotelling H. Applications of the theory of error to the interpretation of trends. J Am Stat Assoc. 1929;24:73–85.

  28. 28.

    Lützen A, de Wind N, Georgijevic D, Nielsen FC, Rasmussen LJ. Functional analysis of HNPCC-related missense mutations in MSH2. Mutat Res. 2008;645:44–55.

  29. 29.

    R Foundation for Statistical Computing. RDCR: a language and environment for statistical computing. Vienna, Austria; 2015.

  30. 30.

    Hinrichsen I, et al. Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis. Clin Cancer Res. 2013;19:2432–2441.

  31. 31.

    Medeiros F, Lindor NM, Couch FJ, Highsmith WE. The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors. J Mol Diagn. 2012;14:264–273.

  32. 32.

    Moghadasi S, et al. The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. J Med Genet. 2018;55:15–20.

  33. 33.

    Rehm HL, et al. ClinGen—the Clinical Genome Resource. N Engl J Med. 2015;372:2235–2242.

  34. 34.

    Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat. 2008;62:314–320.

Download references

Acknowledgements

We appreciate the assistance of John-Paul Plazzer, curator of the International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Database. A.B.S., D.E.G., L.J.R., M.S.G., R.H.S., N.D.W., S.S.W., and S.V.T. are supported by US National Institutes of Health (NIH) National Cancer Institute (NCI) grant R01 CA164944. A.B.S. is supported by an Australian National Health and Medical Research Council (NHMRC) Senior Research Fellowship (ID1061779). B.A.T. is supported by an NHMRC CJ Martin Early Career Fellowship. D.G. was supported in part by an NHMRC grant (ID1109286) G.K. is supported by Harboefonden (grant number 15292), Familien Spogárds Fond, and Fabrikant Einer Willumsens Mindelegat. K.M.B., L.P., and S.V.T. are supported by US NIH NCI grant P30 CA042014. L.J.R. is funded by Nordea-fonden and the Olav Thon Foundation. N.D.W. is funded by the Dutch Digestive Foundation grant FP 16-012.

Author information

Author notes

  1. These authors contributed equally: Lene J. Rasmussen, Marc S. Greenblatt, Niels de Wind, and Sean V. Tavtigian

Affiliations

  1. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

    • Mark Drost PhD
    • , Yvonne Tiersma MS
    •  & Niels de Wind PhD
  2. Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA

    • Bryony A. Thompson PhD
    •  & Sean V. Tavtigian PhD
  3. Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Australia

    • Bryony A. Thompson PhD
  4. Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark

    • Jane H. Frederiksen PhD
    • , Guido Keijzers PhD
    •  & Lene J. Rasmussen PhD
  5. Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia

    • Dylan Glubb PhD
    •  & Amanda B. Spurdle PhD
  6. Department of Microbiology and Molecular Genetics, University of Vermont Robert Larner, M.D. College of Medicine, Burlington, VT, USA

    • Scott Kathe PhD
    •  & Susan S. Wallace PhD
  7. Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    • Jan Osinga BS
    • , Helga Westers PhD
    •  & Rolf H. Sijmons MD, PhD
  8. Department of Medicine, Division of Epidemiology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA

    • Lisa Pappas MS
    •  & Kenneth M. Boucher PhD
  9. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands

    • Siska Molenkamp BS
    • , José B. Zonneveld BS
    •  & Christi J. van Asperen MD, PhD
  10. Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA

    • David E. Goldgar PhD
  11. Department of Medicine and University of Vermont Cancer Center, University of Vermont Robert Larner, M.D. College of Medicine, Burlington, VT, USA

    • Marc S. Greenblatt MD

Authors

  1. Search for Mark Drost PhD in:

  2. Search for Yvonne Tiersma MS in:

  3. Search for Bryony A. Thompson PhD in:

  4. Search for Jane H. Frederiksen PhD in:

  5. Search for Guido Keijzers PhD in:

  6. Search for Dylan Glubb PhD in:

  7. Search for Scott Kathe PhD in:

  8. Search for Jan Osinga BS in:

  9. Search for Helga Westers PhD in:

  10. Search for Lisa Pappas MS in:

  11. Search for Kenneth M. Boucher PhD in:

  12. Search for Siska Molenkamp BS in:

  13. Search for José B. Zonneveld BS in:

  14. Search for Christi J. van Asperen MD, PhD in:

  15. Search for David E. Goldgar PhD in:

  16. Search for Susan S. Wallace PhD in:

  17. Search for Rolf H. Sijmons MD, PhD in:

  18. Search for Amanda B. Spurdle PhD in:

  19. Search for Lene J. Rasmussen PhD in:

  20. Search for Marc S. Greenblatt MD in:

  21. Search for Niels de Wind PhD in:

  22. Search for Sean V. Tavtigian PhD in:

Disclosure

The authors declare no conflicts of interest.

Corresponding authors

Correspondence to Lene J. Rasmussen PhD or Marc S. Greenblatt MD or Niels de Wind PhD or Sean V. Tavtigian PhD.

Electronic supplementary material

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41436-018-0372-2